Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.
Edward B. Garon, MD, MS, professor of medicine, Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, provides an overview of the phase 3 CANOPY-A study (NCT03447769).
In the phase 3, multicenter, double-blind study, investigators examined adjuvant canakinumab (Ilaris) in patients with completely resected non-small cell lung cancer (NSCLC). The primary end point of the study was disease-free survival (DFS) and the secondary end points were overall survival, DFS in PD-L1 subgroups, DFS in CD8 subgroups, lung-cancer-specific survival, and maximum observed plasma concentration of canakinumab.
According to Garon, results from 1382 patients with NSCLC were overall negative as canakinumab failed to meet its primary end point of DFS.
Transcription:
0:08 | The CANOPY-A study was designed as a 1500 patient study to evaluate the potential for canakinumab in patients with completely resected non–small cell lung cancer. The design was a 1:1 randomization between canakinumab every 3 weeks, continuously, vs placebo. The primary end point of the study was disease-free survival, and key secondary end point was overall survival to be tested only if disease-free survival was positive.
0:43 | Unfortunately, the primary end point which was disease-free survival was not positive. Although numerically it did favor canakinumab, particularly at the median, the one-sided P value was 0.26, reflecting the similarity of the curves throughout the entirety of the curve, with a hazard ratio that was not particularly impressive. In addition, when looking for different subgroups, we were not able to find subgroups where the 95% confidence interval excluded 1. As a result, this is a study that was not able to show the value of canakinumab in the setting of completely resected non–small cell lung cancer.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More